Öz
Amaç: Kas güçsüzlüğü ve motor gelişimdeki gecikmeler nörofibromatozis tip 1 olan çocuklarda sık görülen problemlerdir. Kaba Motor Fonksiyon Ölçümü-88, gelişim geriliği olan çocuklarda motor fonksiyonları değerlendirmek için yaygın olarak kullanılan bir araçtır. Bu çalışmanın amacı tip 1 nörofibromatozisli Türk çocuklarından oluşan bir örneklemde Kaba Motor Fonksiyon Ölçümü-88'in geçerliğini araştırmaktır.
Yöntem: Bu çalışmaya nörofibromatozis tip 1 olan 5 ile 17 yaş arası 40 çocuk (20 erkek/20 kız) katıldı. Kaba Motor Fonksiyon Ölçümü-88'in geçerliliğini değerlendirmek için Manuel Kas Testi, fizyoterapist tarafından üst ve alt ekstremitelerde yedi kas grubuna bilateral olarak yapıldı.
Bulgular: Yaş ortalaması 9,7±3,81 yıldı. Manuel Kas Testi ve Kaba Motor Fonksiyon Ölçümü-88 alt boyutları arasında pozitif yönde orta ile güçlü korelasyon bulundu (r=0.317-0.668; p <0.05).
Sonuç: Kaba Motor Fonksiyon Ölçümü-88, nörofibromatozis tip 1 tanılı çocuklarda kaba motor fonksiyonların değerlendirilmesi için geçerli bir ölçümdür. Nörofibromatozis Tip 1’li çocuklarda motor gelişimsel gecikmelerin belirlenmesi, erken müdahale programlarının oluşturulması ve semptoma özgü rehabilitasyon hedeflerinin belirlenmesi için bir rehber olacaktır. Kaba motor fonksiyonu değerlendirmek için Nörofibromatozis tip 1 tanılı çocuklarda Kaba Motor Fonksiyon Ölçümü-88'in kullanılmasını öneriyoruz.
Anahtar Kelimeler
Destekleyen Kurum
Hacettepe Bilimsel Araştırma Projeleri Koordinasyon Birimi
Proje Numarası
THD-2018-16849
Kaynakça
- 1. Gutmann, D.H., et al., Neurofibromatosis type 1. Nat Rev Dis Primers, 2017; 3: 1-17.
- 2. Rietman, A.B., et al., Motor problems in children with neurofibromatosis type 1. J Neurodev Disord, 2017;9: 1-10.
- 3. Miller, D.T., et al., Health supervision for children with neurofibromatosis type 1. Pediatrics, 2019; 143.
- 4. Adair, B., et al., Psychometric properties of functional mobility tools in hereditary spastic paraplegia and other childhood neurological conditions. Dev Med Child Neurol, 2012; 54: 596-605.
- 5. Palisano, R., et al., Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol, 1997; 39: 214-223.
- 6. Lee, B. H. Relationship between gross motor function and the function, activity and participation components of the International Classification of Functioning in children with spastic cerebral palsy. Journal of physical therapy science, 2017; 29, 1732-1736.
- 7. Kerem-Günel, M., Kaba Motor Fonksiyon Ölçütü (KMFÖ-66 & KMFM-88) Kullanıcı Kılavuzu. Kaba Motor Fonksiyon Ölçütü (KMFÖ-66 & KMFM-88) Kullanıcı Kılavuzu, ed. M. Kerem-Günel. 2019, Ankara: Hipokrat
- 8. Russell, D., et al., Evaluating motor function in children with Down syndrome: validity of the GMFM. Dev Med Child Neurol, 1998;40: 693-701.
- 9. Nelson, L., et al., The gross motor function measure™ is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord, 2006;16: 374-380.
- 10. Linder-Lucht, M., et al., Validation of the Gross Motor Function Measure for use in children and adolescents with traumatic brain injuries. Pediatrics, 2007;120: 880-6.
- 11. Salavati, M., et al., Reliability of the modified gross motor function measure-88 (GMFM-88) for children with both spastic cerebral palsy and cerebral visual impairment: a preliminary study. Res Dev Disabil, 2015;45: 32-48.
- 12. Sato, T., et al., The gross motor function measure is valid for Fukuyama congenital muscular dystrophy. Neuromuscul Disord, 2017;27: 45-9.
- 13. DeBella, K., J. Szudek, and J.M. Friedman, Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics, 2000;105: 608-614.
- 14. Florence, J.M., et al., Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy. Phys Ther, 1992;72: 115-122.
- 15. Mahony, K., et al., Inter-tester reliability and precision of manual muscle testing and hand-held dynamometry in lower limb muscles of children with spina bifida. Phys Occup Ther Pediatr, 2009;29: 44-59.
- 16. Manikowska, F., et al., Validation of Manual Muscle Testing (MMT) in children and adolescents with cerebral palsy. NeuroRehabilitation, 2018;42: 1-7.
- 17. Khetani, M.A., et al., Decisional support algorithm for collaborative care planning using the Participation and Environment Measure for Children and Youth (PEM-CY): a mixed methods study. Phys Occup Ther Pediatr, 2015;35: 231-252.
- 18. Cornett, K.M., et al., Muscle weakness in children with neurofibromatosis type 1. Dev Med Child Neurol, 2015;57: 733-736.
Validity of the Gross Motor Function Measurement in a sample of Turkish Children with Neurofibromatosis Type 1
Öz
Purpose: Muscle weakness and delays in motor development are more common problems in children with neurofibromatosis type 1. Gross Motor Function Measurement-88 is widely used tool to evaluate motor functions in children with developmental disabilities. We aimed to investigate validity of the Gross Motor Function Measurement-88 in a sample of Turkish children with neurofibromatosis type 1.
Methods: Aged between 5 to 17 years 40 children (20 male/20 female) with neurofibromatosis type 1 participated in this study. To asses validity of Gross Motor Function Measurement 88, Manual Muscle Test was done seven muscle groups in upper and lower limbs bilaterally by a physical therapist.
Results: The mean age was 9.7±3.81 years. A positive moderate to strong correlation was found between Manual Muscle Test and Gross Motor Function Measurement-88 subdomains (r=0.317-0.668; p <0.05).
Conclusion: Gross Motor Function Measurement-88 is a valid measurement for evaluating gross motor functions in children with neurofibromatosis type 1. Identifying motor developmental delays in children with neurofibromatosis type 1 will be a guide for establishing early intervention programs and determining symptom-specific rehabilitation goals. We recommend the use of Gross Motor Function Measurement-88 in children with neurofibromatosis type 1 for evaluating gross motor function.
Anahtar Kelimeler
Proje Numarası
THD-2018-16849
Kaynakça
- 1. Gutmann, D.H., et al., Neurofibromatosis type 1. Nat Rev Dis Primers, 2017; 3: 1-17.
- 2. Rietman, A.B., et al., Motor problems in children with neurofibromatosis type 1. J Neurodev Disord, 2017;9: 1-10.
- 3. Miller, D.T., et al., Health supervision for children with neurofibromatosis type 1. Pediatrics, 2019; 143.
- 4. Adair, B., et al., Psychometric properties of functional mobility tools in hereditary spastic paraplegia and other childhood neurological conditions. Dev Med Child Neurol, 2012; 54: 596-605.
- 5. Palisano, R., et al., Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol, 1997; 39: 214-223.
- 6. Lee, B. H. Relationship between gross motor function and the function, activity and participation components of the International Classification of Functioning in children with spastic cerebral palsy. Journal of physical therapy science, 2017; 29, 1732-1736.
- 7. Kerem-Günel, M., Kaba Motor Fonksiyon Ölçütü (KMFÖ-66 & KMFM-88) Kullanıcı Kılavuzu. Kaba Motor Fonksiyon Ölçütü (KMFÖ-66 & KMFM-88) Kullanıcı Kılavuzu, ed. M. Kerem-Günel. 2019, Ankara: Hipokrat
- 8. Russell, D., et al., Evaluating motor function in children with Down syndrome: validity of the GMFM. Dev Med Child Neurol, 1998;40: 693-701.
- 9. Nelson, L., et al., The gross motor function measure™ is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord, 2006;16: 374-380.
- 10. Linder-Lucht, M., et al., Validation of the Gross Motor Function Measure for use in children and adolescents with traumatic brain injuries. Pediatrics, 2007;120: 880-6.
- 11. Salavati, M., et al., Reliability of the modified gross motor function measure-88 (GMFM-88) for children with both spastic cerebral palsy and cerebral visual impairment: a preliminary study. Res Dev Disabil, 2015;45: 32-48.
- 12. Sato, T., et al., The gross motor function measure is valid for Fukuyama congenital muscular dystrophy. Neuromuscul Disord, 2017;27: 45-9.
- 13. DeBella, K., J. Szudek, and J.M. Friedman, Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics, 2000;105: 608-614.
- 14. Florence, J.M., et al., Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy. Phys Ther, 1992;72: 115-122.
- 15. Mahony, K., et al., Inter-tester reliability and precision of manual muscle testing and hand-held dynamometry in lower limb muscles of children with spina bifida. Phys Occup Ther Pediatr, 2009;29: 44-59.
- 16. Manikowska, F., et al., Validation of Manual Muscle Testing (MMT) in children and adolescents with cerebral palsy. NeuroRehabilitation, 2018;42: 1-7.
- 17. Khetani, M.A., et al., Decisional support algorithm for collaborative care planning using the Participation and Environment Measure for Children and Youth (PEM-CY): a mixed methods study. Phys Occup Ther Pediatr, 2015;35: 231-252.
- 18. Cornett, K.M., et al., Muscle weakness in children with neurofibromatosis type 1. Dev Med Child Neurol, 2015;57: 733-736.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Makaleler |
| Yazarlar | |
| Proje Numarası | THD-2018-16849 |
| Yayımlanma Tarihi | 30 Nisan 2023 |
| Gönderilme Tarihi | 7 Mayıs 2021 |
| Yayımlandığı Sayı | Yıl 2023 Cilt: 10 Sayı: 1 |
